A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
Study Details
Study Description
Brief Summary
To find a recommended dose of attIL2-T cell therapy that can be given to patients with soft tissue or bone sarcomas and to see if it can help to control the disease.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Primary Objective:
-
Part A. Determine the safety, maximum tolerated dose and/or recommended phase 2 dose of adoptively transferred autologous tumor-targeted IL12 T cells (attIL12 T cell therapy) in combination with cyclophosphamide in patients with advanced/metastatic soft tissue or bone sarcomas
-
Part B. Characterize the safety and tolerability and assess preliminary efficacy of attIL12-armed T cells in combination with cyclophosphamide by evaluating the 4-month disease control rate (DCR4 months) in patients with recurrent unresectable osteosarcoma
Secondary Objectives:
--Evaluate the anti-tumor efficacy achieved following adoptive transfer of autologous tumor-targeted IL12 T cells (attIL12 T cell therapy) in combination with cyclophosphamide in patients with advanced/metastatic soft tissue or bone sarcomas
Exploratory Objectives:
-
Characterize the immune response following adoptive transfer of autologous tumor-targeted IL12 T cells (attIL12 T cell therapy) in paired in pre-treatment and on-treatment tumor specimens and peripheral blood samples
-
Assess FoxP3/CD33/CD8/IFNg expression in pre-treatment and on-treatment tumor specimens and correlate with clinical benefit/anti-tumor response
-
Determine changes in cell surface vimentin (CSV)-positive circulating tumor cells (CTCs) in peripheral blood before and after adoptive transfer of autologous tumor-targeted IL12 T cells (attIL12 T cell therapy) and correlate with clinical benefit/anti-tumor response
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Part A: Dose Findings (MTD) The dose of attIL2-T cell therapy the participants will receive will depend on when the participants joined this study. The first group of participants will receive the lowest dose level of attIL2-T cell therapy. |
Drug: Cyclophosphamide
Given by IV (vein)
Other Names:
Drug: attIL2-T cells
Given by IV (vein)
|
| Experimental: Part B: Osteosarcoma Dose Expansion Participants will receive attIL2-T cell therapy at the recommended dose that was found in Phase 1. |
Drug: Cyclophosphamide
Given by IV (vein)
Other Names:
Drug: attIL2-T cells
Given by IV (vein)
|
Outcome Measures
Primary Outcome Measures
- To examine the incidence of adverse events. [through study completion; an average of 1 year.]
National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. from screening through the treatment period
Eligibility Criteria
Criteria
Inclusion criteria:
-
Age >= 12 years old
-
Histologically-confirmed locally advanced or metastatic soft tissue or bone sarcoma
- Osteosarcoma expansion cohort: histologically confirmed unresectable recurrent/metastatic osteosarcoma
-
Measurable disease according to RECIST 1.1
-
Patients must have received at least 1 prior line of systemic therapy for the treatment of sarcoma, unless no standard therapy exists for a specific sarcoma subtype
-
At least 3 weeks must have elapsed since the last cytotoxic chemotherapy or immunotherapy prior to leukapheresis/PBMC collection. For targeted therapies, at least 4 half-lives or 3 weeks must have elapsed prior to leukapheresis (whichever is shorter).
-
At least 3 weeks must have elapsed since last cytotoxic chemotherapy or immunotherapy prior to starting treatment with cyclophosphamide. For targeted therapies, at least 4 half-lives or 3 weeks must have elapsed prior to initiation of treatment with cyclophosphamide (whichever is shorter).
-
ECOG performance status of 0 or 1 (Performance level as measured by Karnofsky for patients > 16 years of age or Lansky for patients ≤ 16 years of age, see Appendix B)
-
Participants must be willing to undergo core-needle biopsy
-
Patients must have organ and marrow function as defined below
-
Absolute neutrophil count (ANC) > 1 K/uL, Hemoglobin > 9 g/dL, Platelets > 100 K/mm3
-
Serum creatinine </= 2 mg/dL OR creatinine clearance > 50 mL/min
-
Aspartic transaminase (AST) ≤ 1.5 x upper limit of normal (ULN), Alanine transaminase (ALT) </= 1.5 x ULN, Bilirubin ≤ 1.5 x ULN
-
Women of childbearing potential (WOCBP) must agree to use method(s) of contraception: at least one highly effective or two effective accepted methods of contraception to avoid conception throughout the study in such a manner that the risk of pregnancy is minimized. Suggested precautions should be used to minimize the risk or pregnancy for at least 1 month before start of therapy, and while women are on study for up to 3 months after T cell infusion. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal
-
Men must be willing and able to use an acceptable method of birth control such as latex condom during the dosing period and for at least 3 months after completion of the study agent administration (T cell infusion) if their sexual partners are WOCBP.
-
Signed Informed Consent and if applicable, pediatric assent
Exclusion criteria:
-
Known sensitivity to cyclophosphamide and/or study agents
-
Active or prior documented autoimmune disease (including inflammatory bowel disease, celiac disease, Wegener syndrome) within the past 2 years. Subjects with childhood atopy or asthma, vitiligo, alopecia, Hashimoto syndrome, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded
-
Untreated central nervous system metastatic disease, leptomeningeal disease, or cord compression. Subjects previously treated central nervous system metastases that are radiographically and neurologically stable for at least 6 weeks and do not require corticosteroids (of any dose) for symptomatic management for at least 14 days prior to first dose of attIL12-T cells are permitted to enroll.
-
Any concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment. Concurrent use of hormones for non-cancer-related conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptable. In addition, local treatment (eg, by local surgery, radiotherapy, or ablation) of isolated lesions for palliative intent is acceptable beyond 30 days following attIL12 T cell administration with prior consultation and in agreement with the PI.
-
Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5 Grade 0 or 1 with the exception of alopecia and laboratory values listed per the inclusion criteria. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by any of the investigational products may be included (eg, hearing loss) after consultation with the PI.
-
History of primary immunodeficiency, solid organ transplantation, or previous clinical diagnosis of tuberculosis.
-
Receipt of live, attenuated vaccine within 28 days prior to the first dose of investigational products
-
Major surgery (as defined by the investigator) within 4 weeks prior to first dose of treatment or if still recovering from prior surgery.
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs from the study agents, or compromise the ability of the subject to give written informed consent.
- Subjects with cognitive impairment, including adults with cognitive impairment such as trisomy 21 or similar conditions are not specifically excluded from participation, such that appropriate written informed consent is obtained from the parent or legal guardian and they are able to complete with the study protocol requirements and treatment.
-
Active concurrent second malignancy
-
Pregnant or lactating women
-
Any positive test result for hepatitis B or C virus indicating acute or chronic infection
-
Known history of testing positive for human immunodeficiency virus or known acquired immunodeficiency syndrome
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | M D Anderson Cancer Center | Houston | Texas | United States | 77030 |
Sponsors and Collaborators
- M.D. Anderson Cancer Center
Investigators
- Principal Investigator: John Livingston, MD, M.D. Anderson Cancer Center
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 2021-0619
- NCI-2022-09675